Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial

Journal of Clinical Oncology

Volumn 35, Issue 16, 2017, Pages 1786-1796

  André, Marc P E ^a   Girinsky, Théodore ^c   Federico, Massimo ^m   Reman, Oumédaly ^d   Fortpied, Catherine ^b   Gotti, Manuel ⁿ   Casasnovas, Olivier ^g   Brice, Pauline ^e   Van Der Maazen, Richard ^q   Re, Alessandro ^o   Edeline, Véronique ^h   Fermé, Christophe ^c   Van Imhoff, Gustaaf ^r   Merli, Francesco ^p   Bouabdallah, Réda ⁱ   Sebban, Catherine ^j   Specht, Lena ^s   Stamatoullas, Aspasia ^k   Delarue, Richard ^f   Fiaccadori, Valeria ^b   Bellei, Monica ^m   Raveloarivahy, Tiana ^b   Versari, Annibale ^p   Hutchings, Martin ^s   Meignan, Michel ^l   Raemaekers, John ^q   more..

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL DU BOCAGE   (France)

^h INSTITUT CURIE   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j CENTRE LÉON BÉRARD   (France)

^k CENTRE HENRI BECQUEREL   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁿ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^o SPEDALI CIVILI   (Italy)

^p S MARIA NUOVA HOSPITAL   (Italy)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^r UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^s Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HODGKIN DISEASE; HUMAN; INFECTION; INVOLVED NODE RADIOTHERAPY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMORADIOTHERAPY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PROCEDURES; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMORADIOTHERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROCARBAZINE; SURVIVAL RATE; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 85020260335     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.6394     Document Type: Article

References (20)

1. Fermé C, Eghbali H, Meerwaldt JH, et al: Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357: 1916-1927, 2007
2. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640-652, 2010
3. Brusamolino E, Anselmo AP, Klersy C, et al: The risk of acute leukemia in patients treated for Hodgkin’s disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: A case-control study. Haematologica 83:812-823, 1998
4. Schaapveld M, Aleman BM, van Eggermond AM, et al: Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 373:2499-2511, 2015
5. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949-1955, 1993
6. De Bruin ML, Dorresteijn LD, van’t Veer MB, et al: Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928-937, 2009
7. Meyer RM, Gospodarowicz MK, Connors JM, et al: ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366:399-408, 2012
8. Rigacci L, Puccini B, Zinzani PL, et al: The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol 90:499-503, 2015
9. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
10. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
11. Raemaekers JM, André MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
12. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244, 1999
13. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386-2395, 2003 [Erratum: N Engl J Med 353:744, 2005]
14. Girinsky T, Specht L, Ghalibafian M, et al: The conundrum of Hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202-210, 2008
15. Girinsky T, van der Maazen R, Specht L, et al: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79:270-277, 2006
16. Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007
17. Meignan M, Itti E, Bardet S, et al: Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 27:2739-2741, 2009
18. von Tresckow B, Plütschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012
19. Behringer K, Thielen I, Mueller H, et al: Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 23:1818-1825, 2012
20. Radford J, Illidge T, Counsell N, et al: Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598-1607, 2015